Herpes Cure Advocacy goals:

Herpes Simplex Virus Cure and Treatment

National Institutes of Health

• US government funding for the NIH specifically earmarked for Herpes Simplex Virus HSV-1 and HSV-2 therapeutic cure research. Establish a goal of bringing a cure to market as soon as possible or before 2023.
  • Establish specific funding stream for HSV treatment research projects (treatment and vaccine) with a focus on projects with commercial viability
  • Establish NIH grants funding for qualifying HSV research initiatives in the private sector

Herpes Simplex Virus Prevention

Center for Disease Control (CDC)

Herpes Simplex Virus is the largest STI globally with no cure – yet the least spoken about by the CDC. Their policy, recommended by United States Preventative Services Task Force, for not testing or tracking HSV indicates an apathy to spread rather than the strategy of prevention that the public deserves. People deserve to know if they have a chronic infection and also to be protected from partners who don’t know they are a carrier.

Goals for advocacy include:

• US government funding for the Center for Disease Control earmarked specifically for the Sexually Transmitted Disease department to recruit and establish an HSV task force (comprised of CDC staff, volunteer field experts and patient advocates) to be assembled immediately. Within 12 months this group will issue a report with recommendations to;
  • Reduce incidence of HSV in the US
  • Establish step-by-step funding plan for HSV cure research and development
  • Identify potential funding partners
  • Examine CDC STD HSV prevention strategy, evaluate gaps and opportunities to prevent HSV spread in policy and programs.
• Establish follow-up studies to further investigate if HSV spread is reduced when carriers are aware of their status

• Twitter
• Instagram
• Reddit
• Mail

WE NEED YOUR HELP! Learn more about our fundraising goals and donate today.

Have a news tip? Are you working on clinical research for HSV treatments and want to share updates with the public? Let us know!

Never miss a thing. Sign up for emails.